2D |
Two-dimensional |
3D |
Three-dimensional |
ADME |
Absorption, distribution, metabolism, and excretion |
AHO |
Hydroxamic acids inhibitors |
BHMBx |
Training set of N-benzyl-4-((heteroaryl)methyl)benzamides |
BHMVx |
Validation set of N-benzyl-4-((heteroaryl)methyl)benzamides |
CAMD |
computer-aided molecular design |
Eint
|
MM enzyme–inhibitor interaction energy per residue |
ΔΔGcom
|
Relative complexation GFE |
GFE |
Gibbs free energy |
ΔΔGsol
|
Relative solvation GFE |
HBA |
Hydrogen bond Acceptor |
HBD |
Hydrogen bond Donor |
HMM
|
Enthalpy component of GFE |
HOA |
Human oral absorption |
HYD |
Hydrophobic |
HYDA |
Hydrophobic Aliphatic |
IC50
|
Half-maximal inhibitory concentration |
IE |
Interaction energy |
InhA |
2-trans enoyl-acyl carrier protein reductase |
KatG |
Mycobacterium tuberculosis catalase–peroxidase |
LHP |
Large hydrophobic pocket |
LOO |
Leave-one-out cross-validation |
MM |
Molecular mechanics |
MM-PB |
Molecular mechanics–Poisson–Boltzmann |
Mt
|
Mycobacterium tuberculosis
|
MtInhA |
2-trans enoyl-acyl carrier protein reductase of Mycobacterium tuberculosis
|
PDB |
Protein Data Bank |
PfEACP |
2-trans enoyl-acyl carrier protein reductase of Plasmodium falciparum
|
PH4 |
Pharmacophore |
QSAR |
Quantitative structure–activity relationships |
RMSD |
Root-mean square deviation |
SAR |
Structure–activity relationships |
TB |
Tuberculosis |
TS |
Training set |
VS |
Validation set |